Clinical Trial Detail

NCT ID NCT02205398
Title Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

head and neck squamous cell carcinoma

Therapies

INC280 + Cetuximab

Age Groups: adult

Additional content available in CKB BOOST